Turnaround

The future of the BayWa Group hangs in the balance, with its fate being determined not in the boardroom but...

The pharmaceutical packaging group Gerresheimer finds itself in a precarious financial position, despite projecting billions in revenue for the current...

As BioNTech navigates a pivotal transition away from its pandemic-era revenue, the company is asking its shareholders to approve a...

China Pharma Holdings has provided investors with preliminary insights into its performance, despite missing the official deadline for filing its...

A prominent appearance on a major financial television program on April 4, 2026, has drawn increased attention from retail investors...

Bayer faces a period of significant transition as declining revenues from its former blockbuster drugs compel urgent strategic action. The...

The German agricultural trading group BayWa is confronting a perfect storm of legal challenges and financial pressure. Beyond grappling with...

Silver Storm Mining is approaching a pivotal operational transition. The company's primary focus is the planned recommissioning of its La...

Investors in Replimune are positioning for a potential resolution to a prolonged period of uncertainty. The company's stock price advanced...

BioNTech is methodically moving beyond its pandemic legacy. A series of recent strategic decisions—from facility closures and halted trials to...